Treatment of transfusional iron overload due to thalassemia syndromes
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
V VARIOUS
V03 ALL OTHER THERAPEUTIC PRODUCTS
V03A ALL OTHER THERAPEUTIC PRODUCTS
V03AC Iron chelating agents
V03AC02 Deferiprone
D07416 Deferiprone (USAN/INN) <US>
USP drug classification [BR:br08302]
Electrolytes/Minerals/Metals/Vitamins
Electrolyte/Mineral/Metal Modifiers
Deferiprone
D07416 Deferiprone (USAN/INN)
Drug groups [BR:br08330]
Vitamin and mineral
DG01692 Chelator
DG01691 Iron chelator
D07416 Deferiprone
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D07416
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D07416
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D07416